# Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

> **NCT02662062** · PHASE2 · COMPLETED · sponsor: **Australian and New Zealand Urogenital and Prostate Cancer Trials Group** · enrollment: 28 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02662062
- **Lead sponsor:** Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-11
- **Primary completion:** 2022-05-12
- **Final completion:** 2024-08-26
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02662062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02662062, "Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02662062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*